Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 3
2007 2
2008 2
2010 2
2011 5
2012 3
2013 4
2014 7
2015 4
2016 5
2017 1
2018 8
2019 8
2020 8
2021 12
2022 5
2023 11
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Results by year

Filters applied: . Clear all
Page 1
Advancements in small cell lung cancer.
Lee JH, Saxena A, Giaccone G. Lee JH, et al. Among authors: saxena a. Semin Cancer Biol. 2023 Aug;93:123-128. doi: 10.1016/j.semcancer.2023.05.008. Epub 2023 May 24. Semin Cancer Biol. 2023. PMID: 37236329 Review.
Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.
Altorki NK, McGraw TE, Borczuk AC, Saxena A, Port JL, Stiles BM, Lee BE, Sanfilippo NJ, Scheff RJ, Pua BB, Gruden JF, Christos PJ, Spinelli C, Gakuria J, Uppal M, Binder B, Elemento O, Ballman KV, Formenti SC. Altorki NK, et al. Among authors: saxena a. Lancet Oncol. 2021 Jun;22(6):824-835. doi: 10.1016/S1470-2045(21)00149-2. Epub 2021 May 18. Lancet Oncol. 2021. PMID: 34015311 Clinical Trial.
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.
Altorki NK, Walsh ZH, Melms JC, Port JL, Lee BE, Nasar A, Spinelli C, Caprio L, Rogava M, Ho P, Christos PJ, Saxena A, Elemento O, Bhinder B, Ager C, Amin AD, Sanfilippo NJ, Mittal V, Borczuk AC, Formenti SC, Izar B, McGraw TE. Altorki NK, et al. Among authors: saxena a. Nat Commun. 2023 Dec 19;14(1):8435. doi: 10.1038/s41467-023-44195-x. Nat Commun. 2023. PMID: 38114518 Free PMC article.
Ischemic stroke with cancer: Hematologic and embolic biomarkers and clinical outcomes.
Navi BB, Zhang C, Sherman CP, Genova R, LeMoss NM, Kamel H, Tagawa ST, Saxena A, Ocean AJ, Kasner SE, Cushman M, Elkind MSV, Peerschke E, DeAngelis LM. Navi BB, et al. Among authors: saxena a. J Thromb Haemost. 2022 Sep;20(9):2046-2057. doi: 10.1111/jth.15779. Epub 2022 Jun 21. J Thromb Haemost. 2022. PMID: 35652416 Free PMC article.
Systemic therapy for small cell lung cancer.
Levy B, Saxena A, Schneider BJ. Levy B, et al. Among authors: saxena a. J Natl Compr Canc Netw. 2013 Jul;11(7):780-7. doi: 10.6004/jnccn.2013.0100. J Natl Compr Canc Netw. 2013. PMID: 23847216 Review.
Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders.
Srivastava SK, Yadav UC, Reddy AB, Saxena A, Tammali R, Shoeb M, Ansari NH, Bhatnagar A, Petrash MJ, Srivastava S, Ramana KV. Srivastava SK, et al. Among authors: saxena a. Chem Biol Interact. 2011 May 30;191(1-3):330-8. doi: 10.1016/j.cbi.2011.02.023. Epub 2011 Feb 24. Chem Biol Interact. 2011. PMID: 21354119 Free PMC article. Review.
84 results